Detailed Information on Publication Record
2023
RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD
KOBLIZEK, Vladimir, Branislava MILENKOVIC, Michal SVOBODA, Jana KOCIANOVA, Stanislav HOLUB et. al.Basic information
Original name
RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD
Authors
KOBLIZEK, Vladimir (203 Czech Republic), Branislava MILENKOVIC (203 Czech Republic), Michal SVOBODA (203 Czech Republic, belonging to the institution), Jana KOCIANOVA (203 Czech Republic), Stanislav HOLUB (203 Czech Republic), Vladimir ZINDR (203 Czech Republic), Miroslav ILIC (203 Czech Republic), Jelena JANKOVIC (203 Czech Republic), Vojislav CUPURDIJA, Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Boris POPOV and Arschang VALIPOUR
Edition
International Journal of chronic obstructive pulmonary disease, Albany, Dove Medical Press Ltd. 2023, 1178-2005
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30203 Respiratory systems
Country of publisher
New Zealand
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.800 in 2022
RIV identification code
RIV/00216224:14110/23:00133349
Organization unit
Faculty of Medicine
UT WoS
001109137500001
Keywords in English
COPD; survival; mortality; Central and Eastern Europe; respiratory; clinical phenotype; cluster
Tags
International impact, Reviewed
Změněno: 31/1/2024 12:38, Mgr. Tereza Miškechová
Abstract
V originále
Purpose: The Phenotypes of COPD in Central and Eastern Europe (POPE) study assessed the prevalence and clinical characteristics of four clinical COPD phenotypes, but not mortality. This retrospective analysis of the POPE study (RETRO-POPE) investigated the relationship between all-cause mortality and patient characteristics using two grouping methods: clinical phenotyping (as in POPE) and Burgel clustering, to better identify high-risk patients.Patients and Methods: The two largest POPE study patient cohorts (Czech Republic and Serbia) were categorized into one of four clinical phenotypes (acute exacerbators [with/without chronic bronchitis], non-exacerbators, asthma-COPD overlap), and one of five Burgel clusters based on comorbidities, lung function, age, body mass index (BMI) and dyspnea (very severe comorbid, very severe respiratory, moderate-to-severe respiratory, moderate-to-severe comorbid/obese, and mild respiratory). Patients were followed-up for approximately 7 years for survival status.Results: Overall, 801 of 1,003 screened patients had sufficient data for analysis. Of these, 440 patients (54.9%) were alive and 361 (45.1%) had died at the end of follow-up. Analysis of survival by clinical phenotype showed no significant differences between the phenotypes (P=0.211). However, Burgel clustering demonstrated significant differences in survival between clusters (P<0.001), with patients in the "very severe comorbid" and "very severe respiratory" clusters most likely to die. Overall survival was not significantly different between Serbia and the Czech Republic after adjustment for age, BMI, comorbidities and forced expiratory volume in 1 second (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65-0.99; P=0.036 [unadjusted]; HR 0.88, 95% CI 0.7-1.1; P=0.257 [adjusted]). The most common causes of death were respiratory-related (36.8%), followed by cardiovascular (25.2%) then neoplasm (15.2%).Conclusion: Patient clusters based on comorbidities, lung function, age, BMI and dyspnea were more likely to show differences in COPD mortality risk than phenotypes defined by exacerbation history and presence/absence of chronic bronchitis and/or asthmatic features.